REGN: 再生元制药

REGN新闻

• 18:16 4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity (FDMT)
• 17:02 Stock Market Losses Led By Nasdaq, AI Stocks; Goldman, GE, Taiwan Semi, IBM In Focus: Weekly Review
• 13:12 Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
• 11:09 Longleaf Partners Global Fund Q2 2026 Portfolio Review
• 19:33 Baird International And Global Growth Funds Q2 2026 Contributors And Detractors
• 10:38 These biggest and ‘least loved’ stocks are the ones to pick ahead of earnings
• 12:55 Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• 12:46 Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry (NYSE:NVO)
• 16:10 Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• 13:40 Here's Why Regeneron (REGN) is a Strong Value Stock
• 12:55 These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
• 15:55 Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
• 13:50 Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term
• 16:34 What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
• 21:00 Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It (NYSEARCA:XLV)
• 18:39 Healthcare stocks have become a haven for investors ditching tech
• 14:34 Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
• 14:05 BAYRY Stock Surges 17% After Supreme Court Roundup Ruling
• 12:40 Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM)
• 15:11 Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
• 19:00 Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View
• 18:24 Regeneron's Applications for gMG Drug Accepted by FDA and EMA
• 16:55 Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS)
• 14:50 ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout